Table_1_Enhanced NK-92 Cytotoxicity by CRISPR Genome Engineering Using Cas9 Ribonucleoproteins.DOCX
Natural killer (NK) cells are an attractive cell-type for adoptive immunotherapy, but challenges in preparation of therapeutic primary NK cells restrict patient accessibility to NK cell immunotherapy. NK-92 is a well-characterized human NK cell line that has demonstrated promising anti-cancer activities in clinical trials. Unlimited proliferation of NK-92 cells provides a consistent supply of cells for the administration and development of NK cell immunotherapy. However, the clinical efficacy of NK-92 cells has not reached its full potential due to reduced immune functions as compared to primary NK cells. Improvements of NK-92 functions currently rely on conventional transgene delivery by mRNA, plasmid and viral vector with limited efficiencies. To enable precise genetic modifications, we have established a robust CRISPR genome engineering platform for NK-92 based on the nucleofection of Cas9 ribonucleoprotein. To demonstrate the versatility of the platform, we have performed cell-based screening of Cas9 guide RNA, multiplex gene knockout of activating and inhibitory receptors, knock-in of a fluorescent gene, and promoter insertion to reactivate endogenous CD16 and DNAM-1. The CRISPR-engineered NK-92 demonstrated markedly enhanced cytotoxicity and could mediate antibody-dependent cellular cytotoxicity against hard to kill cancer cell lines. Our genome editing platform is straightforward and robust for both functional studies and therapeutic engineering of NK-92 cells.
History
References
- https://doi.org//10.1038/nrc.2015.5
- https://doi.org//10.1016/j.smim.2014.02.002
- https://doi.org//10.1182/blood-2013-10-532531
- https://doi.org//10.1182/blood-2015-12-629055
- https://doi.org//10.1126/scitranslmed.aaf2341
- https://doi.org//10.1158/2326-6066.CIR-15-0118
- https://doi.org//10.3109/14653249.2010.515582
- https://doi.org//10.1056/NEJMoa1910607
- https://doi.org//10.3389/fimmu.2016.00091
- https://doi.org//10.3390/cancers11060769
- https://doi.org//10.1016/j.jcyt.2013.06.017
- https://doi.org//10.1089/10430349950018030
- https://doi.org//10.3109/10428194.2011.634048
- https://doi.org//10.1089/hum.2012.080
- https://doi.org//10.1111/jcmm.12810
- https://doi.org//10.1158/0008-5472.CAN-17-1007
- https://doi.org//10.1038/s41587-019-0325-6
- https://doi.org//10.1101/406934
- https://doi.org//10.3791/58237
- https://doi.org//10.1002/cpmb.43
- https://doi.org//10.7554/eLife.04766
- https://doi.org//10.1101/gr.231936.117
- https://doi.org//10.1371/journal.pone.0060298
- https://doi.org//10.1038/nbt.2647
- https://doi.org//10.1182/bloodadvances.2019000450
- https://doi.org//10.1038/nprot.2013.143
- https://doi.org//10.1101/cshperspect.a016410
- https://doi.org//10.3389/fimmu.2018.00441
- https://doi.org//10.1038/nbt.3437
- https://doi.org//10.1084/jem.20171626
- https://doi.org//10.1038/s41586-018-0326-5
- https://doi.org//10.1038/sj.gt.3303021
- https://doi.org//10.4161/mabs.25077
- https://doi.org//10.18632/oncotarget.5952
- https://doi.org//10.1038/nri.2016.78
- https://doi.org//10.4049/jimmunol.1003389
- https://doi.org//10.1038/sj.leu.2404863
Usage metrics
Read the peer-reviewed publication
Categories
- Transplantation Immunology
- Tumour Immunology
- Immunology not elsewhere classified
- Immunology
- Veterinary Immunology
- Animal Immunology
- Genetic Immunology
- Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)
- Autoimmunity
- Cellular Immunology
- Humoural Immunology and Immunochemistry
- Immunogenetics (incl. Genetic Immunology)
- Innate Immunity